La voie de signalisation PATCHED/Sonic Hedgehog dans le cancer superficiel de la vessie

LaRue, Hélène; Simoneau, Maryse; Aboulkassim, Tahar; Lemieux, Patricia; Girard, Johanne; Hamed, Sahar; Hovington, Hélène; Fradet, Yves

doi:10.1051/medsci/20031910920

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patched 1 (Ptch1) mutation in patients with Gorlin’s syndrome shows early onset of multiple basal cell carcinoma 18 and medulloblastoma 19 . Aberrant Shh expression has been reported in lung 20 , bladder 21 , colorectal 22 , pancreatic 23 and prostate 24 cancer. Shh has been thought to play a critical role in carcinogenesis and metastasis in breast cancers.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh

Noman

Uddin

Rahman

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Dysregulation of Hedgehog (Hh) signaling pathway has been documented in mammary gland development and breast cancer (BC) progression. Despite the remarkable progress in therapeutic interventions, BC related mortality in Bangladesh increased in the last decade. Triple negative breast cancer (TNBC) still presents a critical therapeutic challenge. Thus effective targeted therapy is urgently needed. In this study, we report the clinicopathological characteristics and prognosis of BC patients from Bangladesh. Routine immunohistochemical analysis and high throughput RNA-Seq data from the TCGA library were used to analyze the expression pattern and association of high and low level of Shh expression in a collection of BC patients with a long-term follow-up. High levels of Shh were observed in a subset of BC tumors with poor prognostic pathological features. Higher level of Shh expression correlated with a significantly poorer overall survival of patients compared with patients whose tumors expressed a low level of Shh. These data support the contention that Shh could be a novel biomarker for breast cancer that is involved in mediating the aggressive phenotype of BC. We propose that BC patients exhibiting a higher level of Shh expression, representing a subset of BC patients, would be amenable to Shh targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh

Noman

Uddin

Rahman

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…L'activation constitutive de la voie HH est associée au développement de nombreuses pathologies graves autres que les CBC, ce qui explique que le GDC-0449 représente un grand espoir thérapeutique. Cet inhibiteur a également été testé pour traiter un patient atteint d'un cas extrême de médulloblastome réfractaire à toute thérapie [10], et des essais cliniques pourraient être proposés dans le traitement de cancers colorectaux métastatiques et de cancers ovariens avancés [13]. La voie HH est impliquée dans de nombreux processus biologiques au cours de l'organogenèse.…”

Section: L'activation Constitutive De La Voie Hedgehog Dans La Peau Iunclassified

Les inhibiteurs de la voie Hedgehog

Vidal

2010

Med Sci (Paris)

View full text Add to dashboard Cite

Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer

Chen

Hildebrandt

Clague

et al. 2010

Cancer Prevention Research

View full text Add to dashboard Cite

Sonic hedgehog (Shh) pathway genetic variations may affect bladder cancer risk and clinical outcomes. Therefore, we genotyped 177 single-nucleotide polymorphisms (SNP) in 11 Shh pathway genes in a study including 803 bladder cancer cases and 803 controls. We assessed SNP associations with cancer risk and clinical outcomes in 419 cases of non-muscle-invasive bladder cancer (NMIBC) and 318 cases of muscle-invasive and metastatic bladder cancer (MiMBC). Only three SNPs (GLI3 rs3823720, rs3735361, and rs10951671) reached nominal significance in association with risk (P ≤ 0.05), which became nonsignificant after adjusting for multiple comparisons. Nine SNPs reached a nominally significant individual association with recurrence of NMIBC in patients who received transurethral resection (TUR) only (P ≤ 0.05), of which two (SHH rs1233560 and GLI2 rs11685068) were replicated independently in 356 TUR-only NMIBC patients, with P values of 1.0 × 10 −3 (SHH rs1233560) and 1.3 × 10 −3 (GLI2 rs11685068). Nine SNPs also reached a nominally significant individual association with clinical outcome of NMIBC patients who received Bacillus Calmette-Guérin (BCG; P ≤ 0.05), of which two, the independent GLI3 variants rs6463089 and rs3801192, remained significant after adjusting for multiple comparisons (P = 2 × 10 −4 and 9 × 10 −4 , respectively). The wildtype genotype of either of these SNPs was associated with a lower recurrence rate and longer recurrencefree survival (versus the variants). Although three SNPs (GLI2 rs735557, GLI2 rs4848632, and SHH rs208684) showed nominal significance in association with overall survival in MiMBC patients (P ≤ 0.05), none remained significant after multiple-comparison adjustments. Germ-line genetic variations in the Shh pathway predicted clinical outcomes of TUR and BCG for NMIBC patients.

show abstract

La voie de signalisation PATCHED/Sonic Hedgehog dans le cancer superficiel de la vessie

Cited by 3 publications

References 20 publications

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh

Les inhibiteurs de la voie Hedgehog

Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer

Contact Info

Product

Resources

About